Anti-tumor activity of motesanib in a medullary thyroid cancer model (Q27851632)

13 November 2016

title

Anti-tumor activity of motesanib in a medullary thyroid cancer model (English)

1 reference

13 November 2016

1 reference

A Coxon

1

0 references

J Bready

2

0 references

S Kaufman

3

0 references

J Estrada

4

0 references

T Osgood

5

0 references

J Canon

6

0 references

L Wang

7

0 references

R Radinsky

8

0 references

R Kendall

9

0 references

P Hughes

10

0 references

A Polverino

Journal of Endocrinological Investigation

11

0 references

publication date

February 2012

0 references

published in

0 references

volume

35

0 references

issue

2

0 references

page(s)

181-90

0 references

cites work

Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center

1 reference

12 December 2020

Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas

1 reference

12 December 2020

CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth

1 reference

12 December 2020

Surgical strategy for the treatment of medullary thyroid carcinoma

1 reference

12 December 2020

Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

1 reference

12 December 2020

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

1 reference

12 December 2020

AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology

1 reference

12 December 2020

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

1 reference

12 December 2020

Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour

1 reference

12 December 2020

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

1 reference

12 December 2020

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium

1 reference

12 December 2020

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

1 reference

12 December 2020

Vascular endothelial growth factor: basic science and clinical progress

1 reference

12 December 2020

RET tyrosine kinase signaling in development and cancer

1 reference

12 December 2020

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation

1 reference

12 December 2020

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors

1 reference

12 December 2020

1 reference

12 December 2020

Innovative strategies for the treatment of thyroid cancer

1 reference

12 December 2020

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

1 reference

12 December 2020

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

1 reference

12 December 2020

A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues

1 reference

12 December 2020

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

1 reference

12 December 2020

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer

1 reference

12 December 2020

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

12 December 2020

Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching

1 reference

12 December 2020

Management of the patient with progressive radioiodine non-responsive disease

1 reference

12 December 2020

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

1 reference

12 December 2020

Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid

1 reference

12 December 2020

The biology of VEGF and its receptors

1 reference

12 December 2020

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis

1 reference

12 December 2020

An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway

1 reference

12 December 2020

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

1 reference

12 December 2020

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

12 December 2020

A phase II study of gefitinib in patients with advanced thyroid cancer.

1 reference

12 December 2020

Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia

1 reference

12 December 2020

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features

1 reference

12 December 2020

Angiogenesis in life, disease and medicine

1 reference

12 December 2020

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma

1 reference

12 December 2020

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

1 reference

12 December 2020

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

1 reference

12 December 2020

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)

1 reference

12 December 2020

New therapeutic approaches to treat medullary thyroid carcinoma

1 reference

12 December 2020

Medullary thyroid carcinoma

1 reference

12 December 2020

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

1 reference

12 December 2020

Two functional forms of vascular endothelial growth factor receptor-2/Flk-1 mRNA are expressed in normal rat retina

1 reference

12 December 2020

Phase II trial of sorafenib in advanced thyroid cancer

1 reference

12 December 2020

Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines

1 reference

12 December 2020

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.

1 reference

12 December 2020

Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins

1 reference

12 December 2020

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

1 reference

12 December 2020

Cancer statistics, 2007

1 reference

12 December 2020

Identifiers

1 reference

Dimensions Publication ID

13 November 2016

1078368808

0 references

1 reference